Brivaracetam

	Brivaracetam Struktur
357336-20-0
CAS-Nr.
357336-20-0
Englisch Name:
Brivaracetam
Synonyma:
Briviact;1-PyrrolidineacetaMide, α-ethyl-2-oxo-4-propyl-, (αS,4R)-;UCB 34714;UCB34714;UCB-34714;(S)-2-((R)-2-oxo-4-propylpyrrolidin-1-yl)butanaMide;(2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]butanamide;(alphaS,4R)-alpha-Ethyl-2-oxo-4-propyl-1-pyrrolidineacetamide;Boisitan;Boisetan;UCB-34714;Buvacitan
CBNumber:
CB81508592
Summenformel:
C11H20N2O2
Molgewicht:
212.29
MOL-Datei:
357336-20-0.mol

Brivaracetam Eigenschaften

Schmelzpunkt:
76.38°
alpha 
D25 -60.57° (c = 1 in methanol)
Siedepunkt:
409.3±28.0 °C(Predicted)
Dichte
1.062
storage temp. 
Refrigerator
Löslichkeit
DMSO (Slightly), Methanol (Slightly)
Aggregatzustand
Solid
pka
15.74±0.50(Predicted)
Farbe
White to Off-White
InChI
InChI=1/C11H20N2O2/c1-3-5-8-6-10(14)13(7-8)9(4-2)11(12)15/h8-9H,3-7H2,1-2H3,(H2,12,15)/t8-,9+/s3
InChIKey
MSYKRHVOOPPJKU-MASDURLHNA-N
SMILES
[C@H](N1C(C[C@@H](CCC)C1)=O)(CC)C(=O)N |&1:0,4,r|
Sicherheit
  • Risiko- und Sicherheitserklärung
  • Gefahreninformationscode (GHS)
Bildanzeige (GHS) GHS hazard pictograms
Alarmwort Warnung
Gefahrenhinweise
Code Gefahrenhinweise Gefahrenklasse Abteilung Alarmwort Symbol P-Code
H302 Gesundheitsschädlich bei Verschlucken. Akute Toxizität oral Kategorie 4 Warnung GHS hazard pictogramssrc="/GHS07.jpg" width="20" height="20" /> P264, P270, P301+P312, P330, P501
Sicherheit
P264 Nach Gebrauch gründlich waschen.
P264 Nach Gebrauch gründlich waschen.
P270 Bei Gebrauch nicht essen, trinken oder rauchen.
P301+P312 BEI VERSCHLUCKEN: Bei Unwohlsein GIFTINFORMATIONSZENTRUM/Arzt/... (geeignete Stelle für medizinische Notfallversorgung vom Hersteller/Lieferanten anzugeben) anrufen.
P330 Mund ausspülen.
P501 Inhalt/Behälter ... (Entsorgungsvorschriften vom Hersteller anzugeben) zuführen.

Brivaracetam Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung

Brivaracetam, a novel oral antiepileptic drug with a high affinity for synaptic vesicle protein 2A (SV2A), was approved in Europe and the US as an adjunctive therapy for the treatment of partial onset seizures with or without secondary generalization in patients aged 16 or older.42 Brivaracetam is very closely related to levetiracetam, an antiepileptic treatment whose immediate release formulation has been available in the United States as a generic drug since 2008, but whose extended release formulation is under patent protection until 2028. The two drugs, which were both developed by UCB Pharma, are structurally similar with brivaracetam having an n-propyl group at the C-4 position of the pyrrolidinone ring and levetiracetam having a hydrogen at this same position. A systematic investigation of the various substitutions of levetiracetam resulted in the identification of more potent and selective SV2A ligands and ultimately culminated in the discovery of brivaracetam, which has greater affinity for SV2A, improved selectivity, more rapid brain penetration, and faster onset of action against seizures than levetiracetam.

Verwenden

Treatment ofTreatment of epilepsy, neuropathic pain and essential tremor.

Definition

ChEBI: A non-proteinogenic amino acid derivative that is butanamide in which the pro-S hydrogen at position 2 is replaced by a (4R)-2-oxo-4-propylpyrrolidin-1-yl. Used for treatment of partial onset seizures related to epilepsy.

Nebenwirkungen

Common side effects of brivaracetam include: constipation, nausea, vomiting, extreme tiredness or low energy. Serious side effects that may be caused include: swelling of the face, throat, tongue, lips, and eyes; difficulty swallowing or breathing; hoarseness, hallucinations (seeing things or hearing sounds that are not there), and delusions (strange thoughts or beliefs that have no basis in reality). An overdose may cause: drowsiness, extreme tiredness, dizziness, difficulty maintaining balance, blurred or double vision, slowed heartbeat, nausea, and feeling anxious.

Brivaracetam Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte


Brivaracetam Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global( 332)Lieferanten
Firmenname Telefon E-Mail Land Produktkatalog Edge Rate
Beijing Hope Pharmaceutical Co., Ltd.
+86-010-67886402 +8613611125266
market@hopelife.cn China 71 58
Chengdu Aupone Pharmaceutical Co.Ltd.
+86-28-+86-28-87843998-6060-6060 +8618631098571
lijiaqi@aupone.com China 43 58
Lewoo Pharmatech(Shanghai)Co.,Ltd
+86-15800805830 +86-15800805830
miao@lewoopharma.com.cn China 156 58
Biopole Pharmatech Co., Ltd.
+8615151475053
biopole@163.com China 37 58
Dorne Chemical Technology co. LTD
+86-13583358881 +86-18560316533
Ethan@dornechem.com China 293 58
Firsky International Trade (Wuhan) Co., Ltd
+8615387054039
admin@firsky-cn.com China 436 58
shandong perfect biotechnology co.ltd
+86-53169958659; +8618596095638
sales@sdperfect.com China 294 58
Wuhan Ruichi Technology Co., Ltd
+8613545065237
admin@whrchem.com China 164 58
Shanghai Affida new material science and technology center
+undefined15081010295
2691956269@qq.com China 371 58
Shanghai Daken Advanced Materials Co.,Ltd
+86-371-66670886
info@dakenam.com China 15965 58

  • UCB-34714
  • 2(S)-[2-Oxo-4(R)-propylpyrrolidin-1-yl]butyramide
  • API-Anti Epilepsy
  • brivaracetam
  • BrivaracetamL
  • 1-Pyrrolidineacetamide,a-ethyl-2-oxo-4-propyl-, (aS,4R)-
  • brivaracetam USP/EP/BP
  • Brivaracetam Impurity 43
  • Boisitan
  • Briracetam
  • Eomeprazole
  • (alphaS,4R)-alpha-Ethyl-2-oxo-4-propyl-1-pyrrolidineacetamide
  • 1-PyrrolidineacetaMide, α-ethyl-2-oxo-4-propyl-, (αS,4R)-
  • (S)-2-((R)-2-oxo-4-propylpyrrolidin-1-yl)butanaMide
  • (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]butanamide
  • UCB 34714;UCB34714;UCB-34714
  • Briviact
  • (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]butanam
  • Buvacitan
  • buvacetam
  • Boisetan
  • 357336-20-0
  • 6305-51-2
  • 3573360-20-0
  • API
  • APIs
  • Brain health drug
  • Nootropic
  • 357336-20-0
Copyright 2019 © ChemicalBook. All rights reserved